Paxil CR For PMDD: FDA Decision Expected In “Coming Months,” GSK Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline expects to hear from FDA “in the coming months” on a pending premenstrual dysphoric disorder indication for its antidepressant Paxil CR.